Overview of Atelec

Quick Facts

Property	Description
Active Ingredient	Cilnidipine
Form	Film-coated tablet
Pharmacological Class	Calcium Channel Blocker (Dihydropyridine)
Common Use	Management of high blood pressure (Antihypertensive)
Origin	Synthetic compound, initially developed in Japan

What Type of Medicine is Atelec? The Active Ingredient and Class

Atelec is a prescription-only medication whose single active ingredient is the chemical substance Cilnidipine. It is definitively classified as an antihypertensive drug, belonging to the dihydropyridine subset within the broader pharmacological group known as Calcium Channel Blockers (CCBs). Cilnidipine is recognized for its unique mechanism that helps moderate the body's vascular tone.

As a specialized, later-generation synthetic compound, Cilnidipine was initially developed and recognized in Japan, reflecting a focused effort to refine calcium channel antagonism. The medication is delivered via the oral route, typically formulated as a stable film-coated tablet. Cilnidipine's core function is based on its ability to modulate the flow of calcium ions (Ca^2+) into vascular smooth muscle cells, which consequently leads to the relaxation and widening of arteries.

Understanding Cilnidipine’s Dual Action and General Purpose

The general purpose of Cilnidipine is to effectively and safely manage sustained high blood pressure, known as hypertension. It is clinically recognized for its dual-acting mechanism, which involves blocking both the conventional L-type calcium channels and the less common N-type calcium channels. This functional distinction provides a therapeutic advantage.

Research has demonstrated that this compound is effective in inhibiting N-type calcium channels, thereby reducing the release of the neurotransmitter norepinephrine. This unique action helps reduce the body's stress-related signals that can contribute to high blood pressure. This balanced approach offers a comprehensive way to achieve a vasodepressor effect, which is a key differentiating factor from older CCBs, making it suitable for adult patients requiring stable cardiovascular management.

What side effects are possible with Atelec?

Atelec (cilazapril) is an Angiotensin-Converting Enzyme (ACE) inhibitor, and its safety profile includes common, less common, and serious adverse reactions documented by regulatory authorities.

Common and Less Common Adverse Reactions

The most frequently reported side effects include headache, dizziness, and a dry, persistent cough. Dizziness often occurs when therapy is initiated or the dosage is increased, due to a sudden drop in blood pressure. Other reported effects involve the nervous system (fatigue), skin (rash), and gastrointestinal tract (nausea).

Serious and Clinically Significant Risks

System-Organ Class	Serious Adverse Reaction
Immune System	Angioedema (swelling of the face, lips, tongue, or throat, which can obstruct the airway and be life-threatening).
Vascular	Severe Hypotension (excessive low blood pressure), particularly after the first dose in volume-depleted patients.
Renal	Acute Renal Failure or worsening of existing kidney function, especially in patients with severe congestive heart failure or renal artery stenosis.
Hepatic	Liver disorders including cholestatic hepatitis and elevated liver enzymes.

Safety Restrictions and Monitoring

Atelec is contraindicated in the second and third trimesters of pregnancy due to risk of fetal injury or death. It is also contraindicated in patients with a history of angioedema related to previous ACE inhibitor use, and in patients with diabetes or kidney impairment receiving aliskiren. Monitoring is required for: serum potassium levels (due to risk of hyperkalemia), renal function, and signs of neutropenia (low white blood cell count). Caution is advised when initiating therapy in patients with highly activated blood pressure regulating systems, such as those with severe heart failure or liver cirrhosis.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Atelec (Cilnidipine), a Calcium Channel Blocker, is officially documented as potentially causing an excessive and clinically significant reduction in blood pressure, known as profound hypotension. Other formally recognized manifestations listed in regulatory documents include marked bradycardia (slow heart rate), dizziness, confusion, nausea, and hyperglycemia (elevated blood sugar).

Officially Documented Severity and Actions

The regulatory profile indicates that overdose can lead to life-threatening outcomes, including Cardiogenic Shock, subsequent End-organ injury, and Cardiac Arrest. Due to this critical risk of severe cardiovascular collapse, individuals must seek immediate medical attention for any suspected overexposure.

The government-mandated action requires contacting emergency services or a national Poison Control Center right away. Official management protocols describe the need for continuous cardiac monitoring. Specific supportive measures include the administration of intravenous fluid therapy, vasopressors to manage low blood pressure, and calcium salts used to counteract cardiovascular toxicity. The official documentation also notes that the risk of severe outcomes is increased for the elderly and individuals with pre-existing cardiac impairment.

Therapeutic Uses of Atelec

Atelec is commonly used across conditions characterized by periods of heightened symptoms. The medicine is relevant when supportive symptom management is appropriate.

Managing High Blood Pressure (Hypertension)

This medicine is applied across domains where additional symptomatic support is needed for patients experiencing symptoms related to systemic imbalance due to high blood pressure. It is commonly used across conditions presenting with systemic or localized discomfort. Its approved use is for the management of hypertension. It contributes to easing the overall symptom load associated with elevated pressure.

Control of Episodic and Stress-Related Symptoms

Atelec is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as sudden spikes or fluctuations in blood pressure. It helps address symptom clusters that may become intense or disruptive, used when symptoms create noticeable physiological strain, which in turn assists with maintaining functional stability during periods of increased distress or discomfort.

Quick Fact: May assist with Symptoms related to heightened physiological activity

Providing Long-Term Cardiovascular Support

Applicable in conditions marked by increased physiological stress, Atelec is used in situations involving certain distressing symptoms because it provides support that helps ease the overall symptom burden associated with conditions involving inflammatory or irritative processes. It is relevant for easing symptoms linked to organ-specific functional stress.

Regulatory References

Pharmacy and Poisons Board, Kenya (SmPC for Edecil/Cilnidipine)

Eligibility and Restrictions for Use

Who Can and Cannot Use Atelec?

Atelec (Cilnidipine) is officially indicated for use in the adult population for managing essential hypertension. However, its use is strictly limited or prohibited in several specific groups according to regulatory documentation.

Absolute Contraindications

The medicine is contraindicated and must not be used in patients with known hypersensitivity to the drug or its components. Absolute prohibitions also apply to individuals with severe cardiac instability, including cardiogenic shock, recent myocardial infarction, and acute unstable angina. Furthermore, patients with severe hepatic impairment or severe renal impairment (GFR < 30 mL/min) are ineligible. Patients with specific hereditary metabolic issues, such as galactose intolerance, are also excluded due to tablet excipients.

Age and Life Stage Rules

Atelec is contraindicated for pregnant women or women who may become pregnant. For nursing mothers, use is not recommended; if administration is unavoidable, lactation must be discontinued. Safety and efficacy have not been established in pediatric patients (under 18 years). Conditional use restrictions require special caution for older adults and those with mild to moderate hepatic or renal dysfunction; these patients must be closely monitored.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Atelec (Cilnidipine) based on metabolic pathways and additive pharmacodynamic effects.

Formal Restrictions and Contraindications

Substance / Class	Interaction Classification
Grapefruit or Grapefruit Juice	Formally Contraindicated
Strong Inhibitors of CYP3A4	Formally Contraindicated
Ciclosporin	Formally Contraindicated

Co-administration of the strong CYP3A4 inhibitor class is prohibited because these substances are documented to elevate the blood concentration of Cilnidipine. The consumption of Grapefruit or Grapefruit Juice is similarly restricted due to its inhibitory effect on this metabolic enzyme, increasing drug exposure.

Documented Pharmacokinetic Interactions

Substances that induce hepatic enzymes, such as Rifampicin and certain Anticonvulsant Drugs (e.g., Phenytoin), may reduce the effect of Atelec by accelerating its clearance. Conversely, enzyme modulators like Cimetidine and Azole Antifungal Agents may enhance Cilnidipine's concentration.

Pharmacodynamic and Substance Interactions

Cilnidipine, when combined with other Antihypertensive Agents, Antipsychotic Drugs, or Aldesleukin, carries a documented risk of excessively decreased blood pressure due to an additive effect. Consumption of Alcohol may also potentiate this hypotensive effect. Furthermore, co-administration may increase the plasma concentration of Digoxin, a documented outcome based on reports with related medicines.

Population-Specific Notes

For patients with Serious Hepatic Dysfunction, specific caution is noted in regulatory documents, as the drug’s plasma concentration may become elevated due to impaired clearance.

Mechanism of Action

Atelec (Cilnidipine) operates through a unique dual mechanism that targets two distinct types of calcium channels to modulate vascular smooth muscle and nerve signaling.

Blockade of L-Type Channels and Vasodilation

Cilnidipine acts as an antagonist primarily on L-type voltage-dependent calcium channels (L-VDCC) found in the smooth muscle cells lining the arteries. By blocking these channels, the drug prevents the influx of Ca^2+ ions required for the muscle to contract. This direct molecular interference causes the arterial walls to relax and widen (vasodilation), which reduces the overall Systemic Vascular Resistance (SVR).

Modulation of Peripheral Nerve Signaling via N-Type Channels

The distinguishing feature of the drug is its secondary action: the blockade of N-type voltage-dependent calcium channels (N-VDCC) located on the endings of peripheral sympathetic nerves. This mechanism limits the calcium-dependent release of the vasoconstricting neurotransmitter norepinephrine. By dampening this sympathetic signaling, the drug attenuates reflex tachycardia (increased heart rate) that usually occurs when SVR is lowered, resulting in a reduction of sympathetic counter-regulation.

Dosage and Administration Information

How to Use Atelec

Administration of Atelec (Cilnidipine) is governed by official prescribing information which outlines strict rules for dosage, timing, and patient-specific adjustments.

Official Administration Guidelines

The medication is strictly for oral use as a film-coated tablet in strengths that typically range from 5 mg to 20 mg of the active ingredient. The tablet must be swallowed whole with water, as regulatory instructions prohibit crushing, chewing, or dissolving the formulation.

Feature	Official Instruction
Route of Administration	Exclusively Oral (tablet ingestion).
Dosing Frequency	Once daily.
Timing & Food	Taken after breakfast (i.e., with food).
Starting Dose (Adults)	5 mg once daily.
Maximum Dose	20 mg once daily.

Procedural Usage and Special Populations

The standard protocol for use establishes a once-daily schedule intended for long-term management. The usual starting dose is 5 mg, with a typical maintenance range of 5 mg to 10 mg. Dosage adjustments are specifically addressed for certain groups; for older adults, therapy should be initiated with a lower dose, such as 5 mg, under careful observation.

A key procedural requirement for this therapy involves discontinuation: if Atelec must be stopped, the dosage must be gradually decreased under close medical observation. Abrupt withdrawal is explicitly advised against in official prescribing information as a necessary administration constraint.

Recent Clinical Evidence

Evidence for Use in Essential Hypertension

Research has primarily focused on Atelec within the context of essential hypertension, exploring its role in blood pressure change. The foundation of this evidence relies on Randomized Controlled Trials (RCTs). These trials explored comparisons between Atelec and other types of Calcium Channel Blockers (CCBs) as well as non-CCB medicines like Angiotensin Receptor Blockers (ARBs). Studies monitored outcomes related to systemic or functional imbalance by measuring changes in blood pressure (BP) levels, often tracked both in a clinic setting and over a full 24-hour period. The reports from these trials consistently describe patterns observed in the populations studied, noting the measurements recorded for blood pressure levels during the study period. Comparative evidence contributes to the broader evidence landscape by reporting on patterns observed in heart rate measurements during comparisons with other treatments in the class.

Evidence in Specific High-Risk Populations

Atelec was studied in specific patient populations with co-existing conditions alongside their hypertension. The research has explored patients with co-existing conditions like Chronic Kidney Disease (CKD) or diabetes-related kidney issues (diabetic nephropathy), evaluating specific clinical markers. Studies examined outcomes related to physiological strain, specifically monitoring surrogate markers like the amount of protein or albumin in the urine. These surrogate measures were used in research contexts to monitor kidney function. This focused evidence contributes to the broader evidence landscape for patients with complex clinical presentations.

Limitations and Research Gaps

The research base for Atelec has certain recognized limitations. A significant portion of the primary evidence was observed in some studies conducted mainly in a few Asian countries. Therefore, data for other global populations may remain insufficient. Furthermore, data for certain groups remain insufficient, particularly for patients with multiple serious comorbidities. The most notable research gap concerns hard clinical outcomes. While trials monitored blood pressure changes, comparative evidence is lacking from long-term studies that specifically research examined the incidence of stroke, heart attack, or mortality when comparing Atelec directly against other antihypertensive drugs over many years.

Frequently Asked Questions (FAQ)

Common questions about Atelec (FAQ)

Q: Is Atelec considered a maintenance medicine?

Official prescribing information indicates that Atelec is intended for the long-term management of high blood pressure. It is typically prescribed on a once-daily schedule to support its role in blood pressure management.

Q: Is Atelec the same type of medicine as [similar common drug name]?

Atelec's active ingredient, Cilnidipine, is formally classified as a dihydropyridine Calcium Channel Blocker (CCB). While this places it in the same class as other blood pressure medicines, its unique dual-action mechanism targeting both L-type and N-type calcium channels is a distinguishing feature described in official documents.

Q: Can Atelec affect sleep or cause fatigue?

According to the official product information, fatigue, sleepiness, and insomnia are included among the reported adverse reactions. If these effects occur, they are typically addressed through a healthcare provider.

Q: What kind of monitoring is typically required while a person is on Atelec?

Regular monitoring for specific blood markers is associated with the use of Atelec, according to official documentation. This includes checks for serum potassium levels, renal (kidney) function, and signs of neutropenia (a reduction in white blood cell count).

Q: Can Atelec be taken with other heart medications?

Official regulatory information indicates that taking Atelec with other antihypertensive agents carries a documented risk of excessively low blood pressure. Furthermore, co-administration may increase the plasma concentration of Digoxin, a heart medication.

Q: What are the signs of a possible serious allergic reaction to Atelec?

A serious immune system reaction reported in official documentation is angioedema, which involves potentially life-threatening swelling of the face, lips, tongue, or throat. Other signs of severe reactions, such as liver or blood abnormalities, are also documented by authorities as warranting prompt medical attention.

Q: Is Atelec associated with any liver or kidney function changes?

Official regulatory documents describe that Atelec is associated with certain risks to organ function. These risks include liver disorders, such as elevated liver enzymes and jaundice, and serious risks like acute renal failure or the worsening of existing kidney function.

Q: How quickly does Atelec start working after the first time taking it?

The time it takes for the drug to reach its maximum concentration in the blood, an indicator of the onset of action, is reported to be approximately 1.8 to 3.7 hours after a single dose. Official information describes the medication as exhibiting a gradual antihypertensive action.

Q: Does Atelec have a known risk of dependence?

Atelec (Cilnidipine) is not classified as a controlled substance in regulatory drug schedules. Therefore, the medication is not generally associated with abuse potential or a risk of physical or psychological dependence.

Q: Is it normal to feel a change in heart rate when first starting Atelec?

Official product information notes that Atelec's mechanism of action includes dampening the increase in heart rate (reflex tachycardia) that may occur with other blood pressure medicines. Research reports that this action can reduce heart rate over time.

Q: Is it safe to drive or operate machinery while taking Atelec?

Due to the risk of side effects like dizziness and fatigue, which can be caused by the drug's action to lower blood pressure, regulatory documentation includes a caution. Regulatory documentation includes a caution that patients may be advised to avoid engaging in hazardous activities requiring alertness, such as driving or operating machinery.

Q: What is the difference between Atelec and a generic version?

Atelec is the brand name used for the drug with the active ingredient Cilnidipine. While the active ingredient is identical between the brand and generic versions, they may differ in their inactive components or appearance.

Q: What does 'contraindication' mean in the context of Atelec?

A contraindication is an absolute restriction or circumstance that makes the use of Atelec inadvisable or prohibited, as described in official documentation. Using the medication under a contraindication could pose a significant risk of harm or serious adverse effects.

Q: How long does Atelec stay in the body after the last dose?

The length of time Atelec stays in the body can be estimated by its elimination half-life. Official pharmacological data reports the half-life of Cilnidipine to be approximately 7.5 to 8.1 hours in healthy adults.

Q: What research themes are currently being explored regarding Atelec?

Current research themes are exploring Atelec's effects beyond standard blood pressure reduction. These studies include comparisons with other calcium channel blockers in specific patient groups, such as those with Autosomal Dominant Polycystic Kidney Disease (ADPKD), and evaluation of its potential utility in cardiac conditions like ventricular repolarization delay.

Q: What is the duration of action (how long it lasts) for Atelec?

Clinical studies have demonstrated that the antihypertensive effect of Atelec, when administered once daily, lasts for a full 24 hours. This duration of action is consistent with its prescribed once-daily dosing schedule.

Q: Is Atelec available over the counter?

Official regulatory information clearly classifies Atelec (Cilnidipine) as a prescription-only medication. It is not available for purchase over the counter.

Q: Is Atelec considered a first-line treatment for its primary condition?

Calcium Channel Blockers (CCBs), the class of medicine Atelec belongs to, are generally recommended as one of the established options for first-line therapy in the management of hypertension.

Q: Are there specific patient populations that have been excluded from major Atelec clinical trials?

Clinical trials have specific entry requirements, and certain patient groups are typically excluded. Examples of such excluded populations in specific trials include those with severe cardiovascular or hepatic disorders, as well as women of childbearing potential not using acceptable contraceptive methods.

How should Atelec be stored and disposed of?

How to Store and Dispose of Atelec?

This section outlines the official, labeled storage and disposal requirements for Atelec (cilnidipine) as defined by regulatory authorities.

Storage & Disposal Entity
Storage Temperature	Store at a temperature not exceeding 30 C.
Environmental Protection	Must be protected from light and moisture.
Packaging Rule	Keep the product in its original container or packaging to ensure stability and protection.
Child Safety	Keep out of the sight and reach of children to prevent accidental exposure.
Shelf-Life	The labeled stability is 3 years when stored under the specified conditions.
Disposal	Any unused or expired medicinal product must be disposed of in accordance with local requirements for pharmaceutical waste.

Official labeling mandates that the product be securely stored under 30 C and protected from environmental factors. Use of the product beyond the stated expiry date is prohibited, and proper pharmaceutical disposal procedures must be followed for all waste material.

Atelec